SlideShare a Scribd company logo
Infective endocarditis
Dr. Birhanu Abie ( pediatrician)
University of Gondar March,2020
8/28/2020 1IE
outline
 Introduction
 Epidemiology
 Etiologies
 Pathogenesis
 Clinical manifestation
 diagnosis
 Complication
 Treatment
 References
8/28/2020 2IE
Introduction
 Is an infection of the
endocardium and/or heart valves that
involves thrombus formation
(vegetation), which may damage the
endocardial tissue and/or valves.
 Bacteria are the predominant
microbial pathogens
8/28/2020 3IE
 Nonbacterial endocarditis can be
caused by viruses, fungi, and other
microbiologic agents.
 It is a significant cause of morbidity
and mortality in children and
adolescents despite advances in the
management and prophylaxis of the
disease with antimicrobial agents.
8/28/2020 4IE
 Native or prosthetic heart valves are
the most frequently involved sites.
 Endocarditis also can involve septal
defects, the mural endocardium, or
intravascular foreign devices such as
intracardiac patches, surgically
constructed shunts, and intravenous
catheters.
8/28/2020 5IE
 Infective endarteritis is a similar
clinical illness involving arteries,
including the ductus arteriosus, the
great vessels, aneurysms, or
arteriovenous shunts.
8/28/2020 6IE
EPIDEMIOLOGY
 The prevalence of definite IE was
approximately 12%, and definite or
possible IE was 20%.
 About 35-50% of children with IE have
CHD.
 The risk of IE is increased in patients
with complex cyanotic heart disease,
especially in those who undergo
surgical procedures
8/28/2020 7IE
 The cumulative incidence of IE over
25 years following surgery was
determined for the following CHD
defects.
 Valvular aortic stenosis — 13.3%
 Coarctation of the aorta — 3.5%
 Primum atrial septal defect — 2.8%
 Ventricular septal defect (VSD) — 2.7%
 Tetralogy of Fallot (TOF) — 1.7%
8/28/2020 8IE
ETIOLOGIES
 Gram-positive cocci account for about
90% of recoverable bacteria( Adult
studies)
 Viridans-type streptococci (α-hemolytic
streptococci) and S.aureus remain the
leading causative agents.
 Staphylococcal endocarditis is more
common in patients with no underlying
heart disease.
 viridans group streptococcal infection is
more common after dental procedures.
8/28/2020 9IE
 Group D enterococci are seen more
often after lower bowel or
genitourinary manipulation.
 P.aeruginosa or S.marcescens is seen
more frequently in intravenous drug
users.
 Fungal endocarditis – one of the most
feared forms (complications, like
embolization are common)
8/28/2020 10IE
 Fungal organisms are encountered
after open heart surgery.
 Coagulase-negative staphylococci are
common in the presence of an
indwelling central venous catheter.
 Gram-negative organisms cause
<10% of the endocarditis in children.
8/28/2020 11IE
 Approximately 5% -10% of patients
with endocarditis have negative blood
cultures.
 The most common cause of culture-
negative IE is current or recent
antibiotic therapy or infection caused
by a fastidious organism that grows
poorly in vitro.
8/28/2020 12IE
Pathogenesis
 Turbulent flow traumatizes the
vascular endothelium, creating a
substrate for deposition of fibrin and
platelets, leading to the formation of a
nonbacterial thrombotic embolus
(NBTE).
 Biofilms form on the surface of
implanted mechanical devices such as
valves, catheters, or pacemaker wires
that also serve as the adhesive
substrate for infection.
8/28/2020 13IE
 The development of transient
bacteremia then colonizes this NBTE
or biofilm, leading to proliferation of
bacteria within the lesion.
8/28/2020 14IE
Occurrence of transient bacteremia
Adherence of bacteria to the NBTE
Proliferation of bacteria with in the
vegetation
 Large fibrin deposit encase the bacteria
inside
 Prevent phagocytosis and anti-microbial
penetration
8/28/2020 15IE
 Virtually all vegetations occur in areas
where there is a pressure gradient with
resulting turbulence of blood flow.
 The sites of high-velocity jets where
most IE vegetations occur are on the
atrial side of the atrioventricular valves
and the ventricular side of the semilunar
valves.
 In ≈30% of patients with infective
endocarditis, a predisposing factor is
presumably recognized.
8/28/2020 16IE
Relative risk of IE for underlying
cardiac lesions & conditions
High risk:
prosthetic valves
Previous episode of endocarditis
Complex cyanotic congenital heart
diseases (e.g. single ventricle states,
TGA, TOF)
Surgically corrected systemic artery to
pulmonary artery shunts
Injection drug use
Indwelling central venous catheters
8/28/2020 17IE
Moderate risk
uncorrected PDA
Uncorrected VSD
Bicuspid Aortic valve
Mitral valve prolapse with regurgitation
Rheumatic mitral or aortic valve
diseases
Hypertrophic cardiomyopathy
8/28/2020 18IE
Negligible risk
 Isolated secundum atrial septal defect
 Surgical repair of ASD, VSD, or PDA
(without residual beyond 6 mo)
 Previous coronary artery bypass graft
surgery
 Mitral valve prolapse without valvar
regurgitation
 Previous rheumatic fever without valvar
dysfunction
 Cardiac pacemakers (intracardiac and
epicardial) and implanted defibrillators
8/28/2020 19IE
Clinical manifestations
Result from:
Hemodynamic and structural changes
caused by the local infection
Embolization from vegetations, or
Immunologic reactions by the host
8/28/2020 20IE
Conti……
HISTORY
 Prior congenital or rheumatic heart
disease
 Preceding dental, urinary tract, or
intestinal procedure
 Intravenous drug use
 Central venous catheter
 Prosthetic heart valve
8/28/2020 21IE
SYMPTOMS
 Non specific symptoms(Fever,Chills,
Arthralgia, myalgia, Malaise,
weakness)
 Chest and abdominal pain
 Dyspnea
 Night sweats
 Weight loss
 CNS manifestations (stroke, seizures,
headache
8/28/2020 22IE
SIGNS
 Elevated temperature
 Tachycardia
 Vascular- Embolic phenomena (Roth spots,
petechiae, splinter nail bed hemorrhages,
CNS or ocular lesions)
 Immune complex phenomena
(glomerulonephritis, arthritis,Osler nodes,
Roth spot, )
 Janeway lesions
 New or changing murmur
 Splenomegaly
8/28/2020 23IE
 Heart failure
 Arrhythmias
 Metastatic infection (arthritis,
meningitis, mycotic arterial aneurysm,
pericarditis, abscesses, septic
pulmonary emboli)
 Clubbing
8/28/2020 24IE
8/28/2020 25IE
8/28/2020 26IE
8/28/2020 27IE
8/28/2020 28IE
DIAGNOSIS
Blood culture
 Three to 5 separate blood collections
should be obtained.
 The timing of collections is not
important because bacteremia can be
expected to be relatively constant.
 In 90% of cases of endocarditis, the
causative agent is recovered from the
first 2 blood cultures
8/28/2020 29IE
 Usually 20 to 30 mL of blood is collected
from an adult patient, but this is not
possible in a small child.
 Thus 1 to 3 mL in infants and young
children and 5 to 7 mL in older children
are optimal.
 Usually, three blood cultures are
obtained by separate venipunctures on
the first day, and if there is no growth by
the second day of incubation, two more
may be obtained. 8/28/2020 30IE
 Antimicrobial pretreatment of the patient
reduces the yield of blood cultures to 50-
60%
 Echocardiography
◦ evidence of valve vegetations,
◦ prosthetic valve dysfunction or leak,
◦ myocardial abscess,
◦ new-onset valve insufficiency
◦ predicting embolic complications( fungating
mass >1cm in size)
◦ sensitivities in children reported to be >80%
8/28/2020 31IE
Other laboratory findings
 Elevated erythrocyte sedimentation rate; may be low
with heart or renal failure
 Elevated C-reactive protein
 Anemia
 Leukocytosis
 Immune complexes
 Hypergammaglobulinemia
 Hypocomplementemia
 Rheumatoid factor
 Hematuria
 Renal failure: azotemia, high creatinine
(glomerulonephritis)
 Chest radiograph: bilateral infiltrates, nodules, pleural
effusions
8/28/2020 32IE
Duke crteria
Major criteria
1) positive blood cultures (2 separate
cultures for a usual pathogen, 1 or more
for less-typical pathogens), and
2) evidence of endocarditis on
echocardiography
-intracardiac mass on a valve or other site
-regurgitant flow near a prosthesis
-abscess
-partial dehiscence of prosthetic valves, or
- new valve regurgitant flow
8/28/2020 33IE
Minor criteria
 Predisposing conditions,
 fever,
 Embolic-vascular signs,
 Emmune complex phenomena
(glomerulonephritis, arthritis, rheumatoid
factor, Osler nodes, Roth spots),
 A single, positive blood culture or
 Serologic evidence of infection, and
 Echocardiographic signs not meeting the
major criteria.
8/28/2020 34IE
 clubbing,
 splenomegaly,
 splinter hemorrhages,
 petechiae
 a high erythrocyte sedimentation rate
 a high C-reactive protein level
 the presence of central nonfeeding
lines, peripheral lines,
 microscopic hematuria
8/28/2020 35IE
Definite infective endocarditis (IE):
 Pathologic criteria:
◦ Micro-organisms demonstrated by culture or
histologic examination of a vegetation, a
vegetation that has embolized, or an intracardiac
abscess specimen; or
◦ Pathological lesions; vegetation or intracardiac
abscess confirmed by histologic examination
showing active endocarditis
 Clinical criteria :
◦ 2 major criteria; or
◦ 1 major criterion and 3 minor criteria; or
◦ 5 minor criteria
8/28/2020 36IE
Possible IE:
◦ 1 major criterion and 1 minor criterion; or
3 minor criteria
Rejected IE:
◦ Firm alternative diagnosis explaining
evidence of IE; or
◦ Resolution of IE syndrome with antibiotic
therapy for 4 days; or
◦ No pathologic evidence of IE at surgery or
autopsy, with antibiotic therapy for 4 days; or
◦ Does not meet criteria for possible IE as
above
8/28/2020 37IE
COMPLICATIONS
 PREDISPOSING FACTORS
◦ Prosthetic cardiac valves
◦ Left-sided involvement
◦ Staphylococcus aureus or fungal IE
◦ Previous IE
◦ Prolonged symptoms ≥3 months
◦ Cyanotic congenital heart disease
◦ Systemic-to-pulmonary shunts
◦ Poor clinical response to antimicrobial
therapy
◦ Vegetation size >10mm
8/28/2020 38IE
 Heart failure
 Myocardial abscess
 Toxic myocarditis
 Arrhythemia
 mycotic aneurysms,
 rupture of a sinus of Valsalva,
 obstruction of a valve secondary to large
vegetations
 Thromboembolic phenomenon
 Heart block
8/28/2020 39IE
 meningitis,
 osteomyelitis,
 arthritis,
 renal abscess,
 purulent pericarditis, and
 immune complex-mediated
glomerulonephritis
8/28/2020 40IE
treatment
Antimicrobial
 General principles
◦ Prolonged periods of treatment(4 to 6
weeks)
◦ Bacteriocidal rather than bacteriostatic
◦ Parentral antibiotic
◦ High dose
◦ Combination of antibiotic which have
synergistic effect
◦ Managed in hospital initialy
8/28/2020 41IE
 Antibiotic therapy should be instituted
immediately once a definitive
diagnosis is made.
 outpatient therapy can be undertaken
if the patient is afebrile, has negative
blood cultures, and is at negligible
risk for complications.
 Empiric therapy should cover
staphylococci, streptococci, and
enterococci.
8/28/2020 42IE
 Most patients with IE become afebrile
5-6 days after treatment is begun with
an appropriate antibiotic.
 Patients with S. aureus endocarditis
may respond somewhat more slowly,
remaining febrile for 5-7 days after the
institution of therapy
8/28/2020 43IE
 The initial microbiologic response to
therapy should be assessed by
obtaining repeat blood cultures 48 -72
hours after antibiotics are begun.
8/28/2020 44IE
Surgical management
 INDICATIONS
◦ Severe aortic, mitral or prosthetic valve
involvement with intractable heart failure.
◦ Mycotic aneurysm
◦ Rupture of an aortic sinus
◦ Intraseptal abscess causing complete
heart block
◦ Dehiscence of an intracardiac patch
◦ Fungal endocarditis
8/28/2020 45IE
◦ Failure to sterilize the blood despite
adequate antibiotic levels in 7-10 days
◦ Increasing size of vegetations while
receiving therapy.
8/28/2020 46IE
PROPHYLAXIS
 Prosthetic cardiac valve
 Previous infective endocarditis
8/28/2020 47IE
CONGENITAL HEART DISEASE
(CHD)
 Unrepaired cyanotic CHD
 Completely repaired CHD with
prosthetic material or device during
the 1st 6 mo after the procedure
 Repaired CHD with residual defects
 Cardiac transplantation recipients who
develop cardiac valvulopathy.
8/28/2020 48IE
reference
 Nelson 20th edition
 Moss and Adams cardiology 7th edition
 Uptodate 20.2
8/28/2020 49IE

More Related Content

What's hot

Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
Prof Vijayraddi
 
INFECTIVE ENDOCARDITIS IN CHILDREN
INFECTIVE ENDOCARDITIS IN CHILDRENINFECTIVE ENDOCARDITIS IN CHILDREN
INFECTIVE ENDOCARDITIS IN CHILDREN
Dr. Murtaza Kamal MD,DNB,DrNB Ped Cardiology
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
DrAnsuman Dash
 
Endocarditis
Endocarditis Endocarditis
Endocarditis
Chinna Chadayan
 
Congestive heart failure revised
Congestive heart failure revisedCongestive heart failure revised
Congestive heart failure revised
pediatricsmgmcri
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
Nilesh Jadhav
 
Acute viral myocarditis
Acute viral  myocarditisAcute viral  myocarditis
Acute viral myocarditis
Dr. Saad Saleh Al Ani
 
Myocarditis
MyocarditisMyocarditis
Myocarditis
magdy elmasry
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
Sameh Abdel-ghany
 
Pediatric cardiomyopathy
Pediatric cardiomyopathyPediatric cardiomyopathy
Pediatric cardiomyopathy
Kesava Ananth Ramakrishnan
 
Heart failure in children 2021
Heart failure in children 2021Heart failure in children 2021
Heart failure in children 2021
Imran Iqbal
 
Heart failure in children
Heart failure in childrenHeart failure in children
Heart failure in children
Azad Haleem
 
Acute kidney injury in children 2018
Acute kidney injury in children 2018Acute kidney injury in children 2018
Acute kidney injury in children 2018
Raghav Kakar
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
Centro Escolar University-Makati
 
Acute post streptococcal glomerulonephritis
Acute post streptococcal glomerulonephritisAcute post streptococcal glomerulonephritis
Acute post streptococcal glomerulonephritis
Mohammad Manzoor
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
hospital
 
ENDOCARDITIS
ENDOCARDITISENDOCARDITIS
ENDOCARDITIS
APOLLO JAMES
 
Cardiogenic Shock
Cardiogenic ShockCardiogenic Shock
Cardiogenic Shock
Andrew Ferguson
 
Myocarditis in children
Myocarditis in childrenMyocarditis in children
Myocarditis in children
Pradeep Singh
 
Endocarditis and its management
Endocarditis and its managementEndocarditis and its management
Endocarditis and its management
Shweta Sharma
 

What's hot (20)

Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
 
INFECTIVE ENDOCARDITIS IN CHILDREN
INFECTIVE ENDOCARDITIS IN CHILDRENINFECTIVE ENDOCARDITIS IN CHILDREN
INFECTIVE ENDOCARDITIS IN CHILDREN
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
 
Endocarditis
Endocarditis Endocarditis
Endocarditis
 
Congestive heart failure revised
Congestive heart failure revisedCongestive heart failure revised
Congestive heart failure revised
 
Acute kidney injury
Acute kidney injuryAcute kidney injury
Acute kidney injury
 
Acute viral myocarditis
Acute viral  myocarditisAcute viral  myocarditis
Acute viral myocarditis
 
Myocarditis
MyocarditisMyocarditis
Myocarditis
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
 
Pediatric cardiomyopathy
Pediatric cardiomyopathyPediatric cardiomyopathy
Pediatric cardiomyopathy
 
Heart failure in children 2021
Heart failure in children 2021Heart failure in children 2021
Heart failure in children 2021
 
Heart failure in children
Heart failure in childrenHeart failure in children
Heart failure in children
 
Acute kidney injury in children 2018
Acute kidney injury in children 2018Acute kidney injury in children 2018
Acute kidney injury in children 2018
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
 
Acute post streptococcal glomerulonephritis
Acute post streptococcal glomerulonephritisAcute post streptococcal glomerulonephritis
Acute post streptococcal glomerulonephritis
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
 
ENDOCARDITIS
ENDOCARDITISENDOCARDITIS
ENDOCARDITIS
 
Cardiogenic Shock
Cardiogenic ShockCardiogenic Shock
Cardiogenic Shock
 
Myocarditis in children
Myocarditis in childrenMyocarditis in children
Myocarditis in children
 
Endocarditis and its management
Endocarditis and its managementEndocarditis and its management
Endocarditis and its management
 

Similar to Infective endocarditis in children

IEPPT-IIIstd (2).pptx
IEPPT-IIIstd (2).pptxIEPPT-IIIstd (2).pptx
IEPPT-IIIstd (2).pptx
yilkalmossie1
 
Bacterial endocarditis
Bacterial  endocarditisBacterial  endocarditis
Bacterial endocarditis
Sakina Musa
 
Infective endocarditis updated
Infective endocarditis updatedInfective endocarditis updated
Infective endocarditis updated
Tasneem Bashir • تسنيم بشير
 
Infective endocarditis in children.pptx
Infective endocarditis in children.pptxInfective endocarditis in children.pptx
Infective endocarditis in children.pptx
SabonaLemessa2
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
Kerolus Shehata
 
Infective endocarditis FINAL.pptx
Infective endocarditis FINAL.pptxInfective endocarditis FINAL.pptx
Infective endocarditis FINAL.pptx
RashiSrivastava62
 
infective endocarditis a complete presentation.ppt
infective endocarditis a complete presentation.pptinfective endocarditis a complete presentation.ppt
infective endocarditis a complete presentation.ppt
tejasnangalia07
 
Infective endocarditis 2020
Infective endocarditis 2020Infective endocarditis 2020
Infective endocarditis 2020
Nitin Das
 
infectiveendocarditis-july2015-190917173103.pdf
infectiveendocarditis-july2015-190917173103.pdfinfectiveendocarditis-july2015-190917173103.pdf
infectiveendocarditis-july2015-190917173103.pdf
HaroonButt17
 
Infective endocarditis
Infective endocarditis Infective endocarditis
Infective endocarditis
ikramdr01
 
INFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptxINFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptx
HanaaMohamedSheikhOm
 
Infective Endocarditis (IE) Lecture pptx
Infective Endocarditis (IE) Lecture pptxInfective Endocarditis (IE) Lecture pptx
Infective Endocarditis (IE) Lecture pptx
Shashi Prakash
 
infectiveendocarditis-july2015-190917173103.ppt
infectiveendocarditis-july2015-190917173103.pptinfectiveendocarditis-july2015-190917173103.ppt
infectiveendocarditis-july2015-190917173103.ppt
jenishJebadurai1
 
4_6030689835172236523.pptx
4_6030689835172236523.pptx4_6030689835172236523.pptx
4_6030689835172236523.pptx
JibrilAliSe
 
Infective endocarditis.pptx
Infective endocarditis.pptxInfective endocarditis.pptx
Infective endocarditis.pptx
aishanteme
 
murtazaieppt-190820183045.pdf
murtazaieppt-190820183045.pdfmurtazaieppt-190820183045.pdf
murtazaieppt-190820183045.pdf
HariKrishnanElangova
 
Endocardite infecciosa
Endocardite infecciosaEndocardite infecciosa
Endocardite infecciosa
gisa_legal
 
infectiveendocarditis ppt.pptx
infectiveendocarditis ppt.pptxinfectiveendocarditis ppt.pptx
infectiveendocarditis ppt.pptx
SonuPaul8
 
INFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptxINFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptx
BadarJamal4
 
Endocarditis
EndocarditisEndocarditis
Endocarditis
Rahul Kshirsagar
 

Similar to Infective endocarditis in children (20)

IEPPT-IIIstd (2).pptx
IEPPT-IIIstd (2).pptxIEPPT-IIIstd (2).pptx
IEPPT-IIIstd (2).pptx
 
Bacterial endocarditis
Bacterial  endocarditisBacterial  endocarditis
Bacterial endocarditis
 
Infective endocarditis updated
Infective endocarditis updatedInfective endocarditis updated
Infective endocarditis updated
 
Infective endocarditis in children.pptx
Infective endocarditis in children.pptxInfective endocarditis in children.pptx
Infective endocarditis in children.pptx
 
Infective Endocarditis
Infective EndocarditisInfective Endocarditis
Infective Endocarditis
 
Infective endocarditis FINAL.pptx
Infective endocarditis FINAL.pptxInfective endocarditis FINAL.pptx
Infective endocarditis FINAL.pptx
 
infective endocarditis a complete presentation.ppt
infective endocarditis a complete presentation.pptinfective endocarditis a complete presentation.ppt
infective endocarditis a complete presentation.ppt
 
Infective endocarditis 2020
Infective endocarditis 2020Infective endocarditis 2020
Infective endocarditis 2020
 
infectiveendocarditis-july2015-190917173103.pdf
infectiveendocarditis-july2015-190917173103.pdfinfectiveendocarditis-july2015-190917173103.pdf
infectiveendocarditis-july2015-190917173103.pdf
 
Infective endocarditis
Infective endocarditis Infective endocarditis
Infective endocarditis
 
INFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptxINFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptx
 
Infective Endocarditis (IE) Lecture pptx
Infective Endocarditis (IE) Lecture pptxInfective Endocarditis (IE) Lecture pptx
Infective Endocarditis (IE) Lecture pptx
 
infectiveendocarditis-july2015-190917173103.ppt
infectiveendocarditis-july2015-190917173103.pptinfectiveendocarditis-july2015-190917173103.ppt
infectiveendocarditis-july2015-190917173103.ppt
 
4_6030689835172236523.pptx
4_6030689835172236523.pptx4_6030689835172236523.pptx
4_6030689835172236523.pptx
 
Infective endocarditis.pptx
Infective endocarditis.pptxInfective endocarditis.pptx
Infective endocarditis.pptx
 
murtazaieppt-190820183045.pdf
murtazaieppt-190820183045.pdfmurtazaieppt-190820183045.pdf
murtazaieppt-190820183045.pdf
 
Endocardite infecciosa
Endocardite infecciosaEndocardite infecciosa
Endocardite infecciosa
 
infectiveendocarditis ppt.pptx
infectiveendocarditis ppt.pptxinfectiveendocarditis ppt.pptx
infectiveendocarditis ppt.pptx
 
INFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptxINFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptx
 
Endocarditis
EndocarditisEndocarditis
Endocarditis
 

Recently uploaded

How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
Gokuldas Hospital
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Kunj Vihari
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Kosmoderma Academy Of Aesthetic Medicine
 
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdfOphthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
MuhammadMuneer49
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.
KULDEEP VYAS
 
Skin Diseases That Happen During Summer.
 Skin Diseases That Happen During Summer. Skin Diseases That Happen During Summer.
Skin Diseases That Happen During Summer.
Gokuldas Hospital
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
Gokuldas Hospital
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Breast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapyBreast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapy
Dr. Sumit KUMAR
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
DrGirishJHoogar
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfNAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Rahul Sen
 

Recently uploaded (20)

How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.How to Control Your Asthma Tips by gokuldas hospital.
How to Control Your Asthma Tips by gokuldas hospital.
 
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
 
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdfOphthalmic drugs latest. Xxxxxxzxxxxxx.pdf
Ophthalmic drugs latest. Xxxxxxzxxxxxx.pdf
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.SENSORY NEEDS B.SC. NURSING SEMESTER II.
SENSORY NEEDS B.SC. NURSING SEMESTER II.
 
Skin Diseases That Happen During Summer.
 Skin Diseases That Happen During Summer. Skin Diseases That Happen During Summer.
Skin Diseases That Happen During Summer.
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Breast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapyBreast cancer: Post menopausal endocrine therapy
Breast cancer: Post menopausal endocrine therapy
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfNAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
 

Infective endocarditis in children

  • 1. Infective endocarditis Dr. Birhanu Abie ( pediatrician) University of Gondar March,2020 8/28/2020 1IE
  • 2. outline  Introduction  Epidemiology  Etiologies  Pathogenesis  Clinical manifestation  diagnosis  Complication  Treatment  References 8/28/2020 2IE
  • 3. Introduction  Is an infection of the endocardium and/or heart valves that involves thrombus formation (vegetation), which may damage the endocardial tissue and/or valves.  Bacteria are the predominant microbial pathogens 8/28/2020 3IE
  • 4.  Nonbacterial endocarditis can be caused by viruses, fungi, and other microbiologic agents.  It is a significant cause of morbidity and mortality in children and adolescents despite advances in the management and prophylaxis of the disease with antimicrobial agents. 8/28/2020 4IE
  • 5.  Native or prosthetic heart valves are the most frequently involved sites.  Endocarditis also can involve septal defects, the mural endocardium, or intravascular foreign devices such as intracardiac patches, surgically constructed shunts, and intravenous catheters. 8/28/2020 5IE
  • 6.  Infective endarteritis is a similar clinical illness involving arteries, including the ductus arteriosus, the great vessels, aneurysms, or arteriovenous shunts. 8/28/2020 6IE
  • 7. EPIDEMIOLOGY  The prevalence of definite IE was approximately 12%, and definite or possible IE was 20%.  About 35-50% of children with IE have CHD.  The risk of IE is increased in patients with complex cyanotic heart disease, especially in those who undergo surgical procedures 8/28/2020 7IE
  • 8.  The cumulative incidence of IE over 25 years following surgery was determined for the following CHD defects.  Valvular aortic stenosis — 13.3%  Coarctation of the aorta — 3.5%  Primum atrial septal defect — 2.8%  Ventricular septal defect (VSD) — 2.7%  Tetralogy of Fallot (TOF) — 1.7% 8/28/2020 8IE
  • 9. ETIOLOGIES  Gram-positive cocci account for about 90% of recoverable bacteria( Adult studies)  Viridans-type streptococci (α-hemolytic streptococci) and S.aureus remain the leading causative agents.  Staphylococcal endocarditis is more common in patients with no underlying heart disease.  viridans group streptococcal infection is more common after dental procedures. 8/28/2020 9IE
  • 10.  Group D enterococci are seen more often after lower bowel or genitourinary manipulation.  P.aeruginosa or S.marcescens is seen more frequently in intravenous drug users.  Fungal endocarditis – one of the most feared forms (complications, like embolization are common) 8/28/2020 10IE
  • 11.  Fungal organisms are encountered after open heart surgery.  Coagulase-negative staphylococci are common in the presence of an indwelling central venous catheter.  Gram-negative organisms cause <10% of the endocarditis in children. 8/28/2020 11IE
  • 12.  Approximately 5% -10% of patients with endocarditis have negative blood cultures.  The most common cause of culture- negative IE is current or recent antibiotic therapy or infection caused by a fastidious organism that grows poorly in vitro. 8/28/2020 12IE
  • 13. Pathogenesis  Turbulent flow traumatizes the vascular endothelium, creating a substrate for deposition of fibrin and platelets, leading to the formation of a nonbacterial thrombotic embolus (NBTE).  Biofilms form on the surface of implanted mechanical devices such as valves, catheters, or pacemaker wires that also serve as the adhesive substrate for infection. 8/28/2020 13IE
  • 14.  The development of transient bacteremia then colonizes this NBTE or biofilm, leading to proliferation of bacteria within the lesion. 8/28/2020 14IE
  • 15. Occurrence of transient bacteremia Adherence of bacteria to the NBTE Proliferation of bacteria with in the vegetation  Large fibrin deposit encase the bacteria inside  Prevent phagocytosis and anti-microbial penetration 8/28/2020 15IE
  • 16.  Virtually all vegetations occur in areas where there is a pressure gradient with resulting turbulence of blood flow.  The sites of high-velocity jets where most IE vegetations occur are on the atrial side of the atrioventricular valves and the ventricular side of the semilunar valves.  In ≈30% of patients with infective endocarditis, a predisposing factor is presumably recognized. 8/28/2020 16IE
  • 17. Relative risk of IE for underlying cardiac lesions & conditions High risk: prosthetic valves Previous episode of endocarditis Complex cyanotic congenital heart diseases (e.g. single ventricle states, TGA, TOF) Surgically corrected systemic artery to pulmonary artery shunts Injection drug use Indwelling central venous catheters 8/28/2020 17IE
  • 18. Moderate risk uncorrected PDA Uncorrected VSD Bicuspid Aortic valve Mitral valve prolapse with regurgitation Rheumatic mitral or aortic valve diseases Hypertrophic cardiomyopathy 8/28/2020 18IE
  • 19. Negligible risk  Isolated secundum atrial septal defect  Surgical repair of ASD, VSD, or PDA (without residual beyond 6 mo)  Previous coronary artery bypass graft surgery  Mitral valve prolapse without valvar regurgitation  Previous rheumatic fever without valvar dysfunction  Cardiac pacemakers (intracardiac and epicardial) and implanted defibrillators 8/28/2020 19IE
  • 20. Clinical manifestations Result from: Hemodynamic and structural changes caused by the local infection Embolization from vegetations, or Immunologic reactions by the host 8/28/2020 20IE
  • 21. Conti…… HISTORY  Prior congenital or rheumatic heart disease  Preceding dental, urinary tract, or intestinal procedure  Intravenous drug use  Central venous catheter  Prosthetic heart valve 8/28/2020 21IE
  • 22. SYMPTOMS  Non specific symptoms(Fever,Chills, Arthralgia, myalgia, Malaise, weakness)  Chest and abdominal pain  Dyspnea  Night sweats  Weight loss  CNS manifestations (stroke, seizures, headache 8/28/2020 22IE
  • 23. SIGNS  Elevated temperature  Tachycardia  Vascular- Embolic phenomena (Roth spots, petechiae, splinter nail bed hemorrhages, CNS or ocular lesions)  Immune complex phenomena (glomerulonephritis, arthritis,Osler nodes, Roth spot, )  Janeway lesions  New or changing murmur  Splenomegaly 8/28/2020 23IE
  • 24.  Heart failure  Arrhythmias  Metastatic infection (arthritis, meningitis, mycotic arterial aneurysm, pericarditis, abscesses, septic pulmonary emboli)  Clubbing 8/28/2020 24IE
  • 29. DIAGNOSIS Blood culture  Three to 5 separate blood collections should be obtained.  The timing of collections is not important because bacteremia can be expected to be relatively constant.  In 90% of cases of endocarditis, the causative agent is recovered from the first 2 blood cultures 8/28/2020 29IE
  • 30.  Usually 20 to 30 mL of blood is collected from an adult patient, but this is not possible in a small child.  Thus 1 to 3 mL in infants and young children and 5 to 7 mL in older children are optimal.  Usually, three blood cultures are obtained by separate venipunctures on the first day, and if there is no growth by the second day of incubation, two more may be obtained. 8/28/2020 30IE
  • 31.  Antimicrobial pretreatment of the patient reduces the yield of blood cultures to 50- 60%  Echocardiography ◦ evidence of valve vegetations, ◦ prosthetic valve dysfunction or leak, ◦ myocardial abscess, ◦ new-onset valve insufficiency ◦ predicting embolic complications( fungating mass >1cm in size) ◦ sensitivities in children reported to be >80% 8/28/2020 31IE
  • 32. Other laboratory findings  Elevated erythrocyte sedimentation rate; may be low with heart or renal failure  Elevated C-reactive protein  Anemia  Leukocytosis  Immune complexes  Hypergammaglobulinemia  Hypocomplementemia  Rheumatoid factor  Hematuria  Renal failure: azotemia, high creatinine (glomerulonephritis)  Chest radiograph: bilateral infiltrates, nodules, pleural effusions 8/28/2020 32IE
  • 33. Duke crteria Major criteria 1) positive blood cultures (2 separate cultures for a usual pathogen, 1 or more for less-typical pathogens), and 2) evidence of endocarditis on echocardiography -intracardiac mass on a valve or other site -regurgitant flow near a prosthesis -abscess -partial dehiscence of prosthetic valves, or - new valve regurgitant flow 8/28/2020 33IE
  • 34. Minor criteria  Predisposing conditions,  fever,  Embolic-vascular signs,  Emmune complex phenomena (glomerulonephritis, arthritis, rheumatoid factor, Osler nodes, Roth spots),  A single, positive blood culture or  Serologic evidence of infection, and  Echocardiographic signs not meeting the major criteria. 8/28/2020 34IE
  • 35.  clubbing,  splenomegaly,  splinter hemorrhages,  petechiae  a high erythrocyte sedimentation rate  a high C-reactive protein level  the presence of central nonfeeding lines, peripheral lines,  microscopic hematuria 8/28/2020 35IE
  • 36. Definite infective endocarditis (IE):  Pathologic criteria: ◦ Micro-organisms demonstrated by culture or histologic examination of a vegetation, a vegetation that has embolized, or an intracardiac abscess specimen; or ◦ Pathological lesions; vegetation or intracardiac abscess confirmed by histologic examination showing active endocarditis  Clinical criteria : ◦ 2 major criteria; or ◦ 1 major criterion and 3 minor criteria; or ◦ 5 minor criteria 8/28/2020 36IE
  • 37. Possible IE: ◦ 1 major criterion and 1 minor criterion; or 3 minor criteria Rejected IE: ◦ Firm alternative diagnosis explaining evidence of IE; or ◦ Resolution of IE syndrome with antibiotic therapy for 4 days; or ◦ No pathologic evidence of IE at surgery or autopsy, with antibiotic therapy for 4 days; or ◦ Does not meet criteria for possible IE as above 8/28/2020 37IE
  • 38. COMPLICATIONS  PREDISPOSING FACTORS ◦ Prosthetic cardiac valves ◦ Left-sided involvement ◦ Staphylococcus aureus or fungal IE ◦ Previous IE ◦ Prolonged symptoms ≥3 months ◦ Cyanotic congenital heart disease ◦ Systemic-to-pulmonary shunts ◦ Poor clinical response to antimicrobial therapy ◦ Vegetation size >10mm 8/28/2020 38IE
  • 39.  Heart failure  Myocardial abscess  Toxic myocarditis  Arrhythemia  mycotic aneurysms,  rupture of a sinus of Valsalva,  obstruction of a valve secondary to large vegetations  Thromboembolic phenomenon  Heart block 8/28/2020 39IE
  • 40.  meningitis,  osteomyelitis,  arthritis,  renal abscess,  purulent pericarditis, and  immune complex-mediated glomerulonephritis 8/28/2020 40IE
  • 41. treatment Antimicrobial  General principles ◦ Prolonged periods of treatment(4 to 6 weeks) ◦ Bacteriocidal rather than bacteriostatic ◦ Parentral antibiotic ◦ High dose ◦ Combination of antibiotic which have synergistic effect ◦ Managed in hospital initialy 8/28/2020 41IE
  • 42.  Antibiotic therapy should be instituted immediately once a definitive diagnosis is made.  outpatient therapy can be undertaken if the patient is afebrile, has negative blood cultures, and is at negligible risk for complications.  Empiric therapy should cover staphylococci, streptococci, and enterococci. 8/28/2020 42IE
  • 43.  Most patients with IE become afebrile 5-6 days after treatment is begun with an appropriate antibiotic.  Patients with S. aureus endocarditis may respond somewhat more slowly, remaining febrile for 5-7 days after the institution of therapy 8/28/2020 43IE
  • 44.  The initial microbiologic response to therapy should be assessed by obtaining repeat blood cultures 48 -72 hours after antibiotics are begun. 8/28/2020 44IE
  • 45. Surgical management  INDICATIONS ◦ Severe aortic, mitral or prosthetic valve involvement with intractable heart failure. ◦ Mycotic aneurysm ◦ Rupture of an aortic sinus ◦ Intraseptal abscess causing complete heart block ◦ Dehiscence of an intracardiac patch ◦ Fungal endocarditis 8/28/2020 45IE
  • 46. ◦ Failure to sterilize the blood despite adequate antibiotic levels in 7-10 days ◦ Increasing size of vegetations while receiving therapy. 8/28/2020 46IE
  • 47. PROPHYLAXIS  Prosthetic cardiac valve  Previous infective endocarditis 8/28/2020 47IE
  • 48. CONGENITAL HEART DISEASE (CHD)  Unrepaired cyanotic CHD  Completely repaired CHD with prosthetic material or device during the 1st 6 mo after the procedure  Repaired CHD with residual defects  Cardiac transplantation recipients who develop cardiac valvulopathy. 8/28/2020 48IE
  • 49. reference  Nelson 20th edition  Moss and Adams cardiology 7th edition  Uptodate 20.2 8/28/2020 49IE